Optimization of PCR amplification and sequencing of GC-rich protein-coding region of CEBPA (CCAAT/enhancer binding protein alpha) in acute myeloid leukemia patients using betaine.

Fareena Bilwani, Fatima Iqbal, Mohammad Khurshid

Abstract read

In one paragraph

Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Fareena BilwaniDepartment of Biological and Biomedical Sciences, The Aga Khan University, Stadium Road, P.O. Box 3500, Karachi, 74800, Pakistan. fareena.bilwani@aku.edu.ORCID http://orcid.org/0000-0002-5107-4582

Fatima IqbalCentre for Regenerative Medicine & Stem Cell Research, The Aga Khan University, Stadium Road, P.O. Box 3500, Karachi, 74800, Pakistan.

Mohammad KhurshidDepartment of Oncology, Department of Pathology and Laboratory Medicine, The Aga Khan University, Stadium Road, P.O. Box 3500, Karachi, 74800, Pakistan.

Funding

Dr. Aleem Qureshi and Kulsum Aleem Exploratory Grants for Medical Discovery from The Aga Khan University 159National Research Program for Universities from Higher Education Commission of Pakistan 5216Seed Money Grant from The Aga Khan University PF80-0316

6 · The paper itself

Abstract

backgroundCEBPA, a GC rich gene encodes for transcription factor CCAAT/enhancer binding protein alpha (C/EBPα) which is essential for granulocyte development. Mutation(s) in CEBPA leads to block in myeloid cells differentiation which is characteristic of acute myeloid leukemia (AML). In addition, mutation(s) in CEBPA has been associated with prognosis in AML. Therefore, analysis of protein-coding sequence of CEBPA is critical in patients diagnosed with AML. This study aimed to optimize PCR amplification followed by Sanger sequencing of GC rich regions of CEBPA in AML patients using betaine which is a known PCR additive with relatively less inhibitory effect. METHODS AND

resultsPCR amplification using two sets of primer was performed with varying concentrations of betaine and MgCl

conclusionThese findings establish a potentially cost-effective and feasible method for sequencing protein-coding region of CEBPA in AML patients.

Indexed as

BetaineCCAAT-Enhancer-Binding Protein-alphaCCAAT-Enhancer-Binding ProteinsLeukemia, Myeloid, AcutePolymerase Chain ReactionGC Rich SequenceHumansMutationSequence Analysis, DNABetaineCCAAT-Enhancer-Binding Protein-alphaCCAAT-Enhancer-Binding ProteinsCEBPA protein, humanAcute myeloid leukemia.BetaineCCAAT/enhancer binding protein alphaGC-richPolymerase chain reactionSanger sequencing

Identifiers

PMID42455225

DOI10.1007/s11033-026-12388-4

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.